40 CROs Select Veeva Vault CTMS to Drive Clinical Trial Operations

Rhea-AI Summary

On October 17, 2022, Veeva Systems (NYSE: VEEV) announced that 40 contract research organizations (CROs), including four of the top six global CROs, have adopted the Veeva Vault CTMS to enhance clinical trial efficiency. This solution is now used by over 120 sponsors, including nine of the top 20 pharmaceutical companies, establishing it as the industry leader in clinical trial management. The Vault CTMS provides a comprehensive view of trial metrics, improving collaboration and study performance, which is essential for accelerating trial processes.

Positive

• 40 CROs have selected Veeva Vault CTMS, including four of the top six global CROs.
• Over 120 sponsors, including nine of the top 20 pharmaceutical companies, are using Vault CTMS.
• Vault CTMS enhances collaboration and transparency between CROs and sponsors, improving trial execution.

Negative

• None.

Leading CROs unifying trial data and processes for greater visibility and speed

PLEASANTON, Calif. , Oct. 17, 2022 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced that 40 contract research organizations (CROs) selected Veeva Vault CTMS to deliver faster and more efficient trials to sponsors, which includes four of the top six global CROs. These global leaders – Labcorp Drug Development, Parexel, PPD clinical research business of Thermo Fisher Scientific Inc., and Syneos Health – are unifying clinical on a single platform as they expand their use of Veeva Vault Clinical Suite from Vault eTMF to now include Vault CTMS.

Also selected by more than 120 sponsors, including 9 of the top 20 pharmaceutical companies, Vault CTMS has fast become the industry-leading solution for clinical trial management. As CROs increasingly standardize on Vault CTMS, they can support sponsor preference for Veeva Vault while modernizing study operations for more efficient execution.

Vault CTMS provides a complete view of trial metrics so CROs can better manage study performance and increase transparency to sponsors. Sponsors and CROs using Vault CTMS work on a consistent industry standard platform that makes it easier to collaborate and share study information for real-time visibility across the study portfolio.

"Veeva Vault CTMS is the first clinical trial management application developed to meet the needs of both sponsors and CROs," said Henry Galio, vice president, Veeva Vault CTMS. "As more companies advance trial operations with Veeva, sponsors, CROs, and sites can work closer together to drive faster study endpoints and accelerate subject enrollment in trials." 

Vault CTMS is part of the Veeva Vault Clinical Operations Suite, enabling companies to share information and documents across eTMF, CTMS, payments, study start-up, and study training for better collaboration and execution throughout the study lifecycle.

Additional Information
For more on Veeva Vault CTMS, visit: veeva.com/CTMS 
Connect with Veeva on LinkedIn: linkedin.com/company/veeva-systems 
Follow @veevasystems on Twitter: twitter.com/veevasystems

About Veeva Systems
Veeva is the global leader in cloud software for the life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 1,000 customers, ranging from the world's largest pharmaceutical companies to emerging biotechs. As a Public Benefit Corporation, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit veeva.com.

Veeva Forward-looking Statements
This release contains forward-looking statements regarding Veeva's products and services and the expected results or benefits from use of our products and services. These statements are based on our current expectations. Actual results could differ materially from those provided in this release and we have no obligation to update such statements. There are numerous risks that have the potential to negatively impact our results, including the risks and uncertainties disclosed in our filing on Form 10-Q for the period ended July 31, 2022, which you can find here (a summary of risks which may impact our business can be found on pages 39 and 40), and in our subsequent SEC filings, which you can access at sec.gov.

Contact:
Deivis Mercado
Veeva Systems
925-226-8821
deivis.mercado@veeva.com

© 2022 Veeva Systems Inc. All rights reserved. Veeva, V, Vault, and Crossix are registered trademarks of Veeva Systems Inc.

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/40-cros-select-veeva-vault-ctms-to-drive-clinical-trial-operations-301650493.html

SOURCE Veeva Systems

FAQ

What is Veeva Vault CTMS and why is it significant for CROs?

Veeva Vault CTMS is a clinical trial management system selected by numerous CROs for its ability to unify data and improve efficiency in clinical trials.

How many CROs have adopted Veeva Vault CTMS as of October 2022?

As of October 2022, 40 CROs have adopted Veeva Vault CTMS.

Which major CROs are using Veeva Vault CTMS?

Major CROs using Veeva Vault CTMS include Labcorp Drug Development, Parexel, PPD (Thermo Fisher Scientific), and Syneos Health.

What impact does Veeva Vault CTMS have on clinical trial operations?

Veeva Vault CTMS improves clinical trial operations by providing better visibility into trial metrics and facilitating collaboration between sponsors and CROs.

How does Veeva Vault CTMS enhance sponsor collaboration?

It allows sponsors and CROs to work on a consistent platform, improving information sharing and real-time visibility across the study portfolio.